Get in touch with us to discuss your project and discover how the Pioneer Antibody Discovery Platform† can help identify your new therapeutic candidates.
Speak with a Pioneer Platform† ExpertAccelerating Biotherapeutic Antibody Discovery
Cutting-Edge
Technologies
to Redefine
Antibody Discovery
The Pioneer™ Antibody Discovery Platform is designed to swiftly generate diverse, high-affinity therapeutic leads with strong developability profiles.
At the core of this platform are Bio-Rad’s cutting-edge technologies: SpyDisplay and SpyLock. Together, they serve as powerful backup solutions to ensure a seamless, tailored workflow for antibody discovery, with project-specific validation provided by Bio-Rad’s expert team.
SpyDisplay Technology
One vector for both selection and expression
SpyLock Technology
Fast prototyping of bispecific antibodies
Bio-Rad has several assets available for out-licensing, specifically targeting immune checkpoint molecules, cytokine receptors, and GPCRs.
| Target | Format | Stage | Data available | Therapeutic area |
|---|---|---|---|---|
| TIGIT | Fab, IgG | Pre-clinical | Affinity, in vitro cellular functionality, developability assessment | Oncology |
| IL6R | Fab, IgG | Pre-clinical | Affinity, in vitro cellular functionality, developability assessment | Autoimmune disease |
| CXCR4 | Fab | Pre-clinical | Cell binding, in vitro cellular functionality, ligand binding competency, developability assessment, epitope coverage | Oncology, autoimmune disease |
| C5aR | Fab | Pre-clinical | Cell binding, in vitro cellular functionality | Autoimmune disease |
Address
Phone
Email